Research Methodology on Insulin Biosimilars Market
Introduction:
The Market Research Future report titled ‘Insulin Biosimilars Market - Forecast to 2030’ is a comprehensive study that provides market insights into the current and future trends in the global insulin biosimilars industry. The focus of this research is to analyse and estimate the market size and future growth potential of the insulin biosimilars market. This market has been gaining an increasing amount of attention recently due to its potential to provide cost-effective alternatives to expensive biopharmaceuticals. The report is designed to provide an in-depth analysis of the market drivers, restraints, opportunities, and challenges that have an impact on the market.
Research Methodology:
The research methodology adopted for the Market Research Future’s (MRF) report on Insulin Biosimilars Market - Forecast to 2030 includes a comprehensive market analysis with inputs from industry experts. The overall market has been divided into several segments and sub-segments, taking into consideration the product types, applications, major regions, and key players.
The market size estimation and forecasts for the Insulin Biosimilars Market - Forecast to 2030 are obtained through the application of various secondary and primary sources. The data obtained from these sources is then validated by a set of market experts. Various assumptions are also made during the research process such as current market trends and dynamics, current macro- and micro-economic indicators, and other related factors.
The key data points obtained from the secondary sources include an analysis of the global insulin biosimilar market players, product types, applications, major regions, and major countries. A bottom-up market approach has been adopted to estimate the overall global market size. The top-down approach has been used to validate the market size estimated based on the bottom-up approach.
In order to obtain an accurate and comprehensive market estimation and forecasts for the Insulin Biosimilars Market - Forecast to 2030, primary research has been carried out. This included primary interviews with industry experts and market participants. The primary research process included interviews with various companies and industry experts. The questionnaire-based interviews were conducted using a combination of face-to-face, telephone, and online interviews.
Data Analysis and Interpretation:
The market analysis process includes the evaluation of secondary sources, primary sources, and expert interviews to generate market data. The market data is then analyzed and validated using statistical and econometric techniques such as principal component analysis, correlation analysis, multi-variate analysis, K-means clustering, etc. The market analysis also involves the estimation of the market size and future growth potential of the insulin biosimilar industry. This is done by taking into consideration the current market trends, expected market size, and future trends in the global insulin biosimilar industry.
The Market Research Future report on Insulin Biosimilars Market - Forecast to 2030 provides a detailed overview of the market. The report covers the overview and definition of the insulin biosimilar market as well as the product types and applications. It also provides an in-depth analysis of market drivers, restraints, opportunities, and challenges for the insulin biosimilar market. It also covers market segmentation based on product types, applications, major regions, and key players. The report also provides a detailed analysis of the regional markets in terms of market size, growth, and future trends. The report also covers the competitive landscape and SWOT analysis of major players in the insulin biosimilar industry.
Conclusion:
The Market Research Future report on Insulin Biosimilars Market - Forecast to 2030 provides an in-depth analysis of the global insulin biosimilar market and is designed to provide valuable insights to industry stakeholders. The report focuses on the various market dynamics such as market drivers, restraints, opportunities, and challenges. The report also provides a detailed analysis of the regional markets in terms of market size, growth, and future trends. The report also provides a detailed analysis of the competitive landscape and a SWOT analysis of major players in the insulin biosimilar industry.
Table of Contents
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.2.1. Growing Prevalence of Diabetes
4.2.2. Increasing number of clinical trials
4.2.3. Patent expiry of biologics paving way for biosimilars
4.3. Restraints
4.3.1. High cost of production
4.3.2. Stringent approval process for biosimilars
4.4. Opportunities
4.4.1. New product approval and launch
4.4.2. Strategic collaboration for product development
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis/Supply Chain Analysis
5.2.1. Impact of COVID 19 on insulin biosimilars market
5.2.2. Impact on availability Of Drugs And API
5.2.3. Impact on the ongoing clinical trials
5.2.4. Impact on cost of product/therapy
5.2.5. Impact on trade (import/export)
6. GLOBAL INSULIN BIOSIMILARS MARKET, BY TYPE
6.1. Overview
6.2. Rapid-acting Biosimilars
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3. Long-acting Biosimilars
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.4. Premixed Biosimilars
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7. GLOBAL INSULIN BIOSIMILARS MARKET, BY INDICATION
7.1. Overview
7.2. Type I Diabetes
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.3. Type II Diabetes
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
8. GLOBAL INSULIN BIOSIMILARS MARKET, BY REGION
8.1. Overview
8.2. Americas
8.2.1. North America
8.2.1.1. US
8.2.1.2. Canada
8.2.2. Latin America
8.3. Europe
8.3.1. Western Europe
8.3.1.1. Germany
8.3.1.2. France
8.3.1.3. Italy
8.3.1.4. Spain
8.3.1.5. UK
8.3.1.6. Rest of Western Europe
8.3.2. Eastern Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle East & Africa
8.5.1. Middle East
8.5.2. Africa
9. COMPANY LANDSCAPE
9.1.1. Overview
9.1.2. Competitive Analysis
9.1.3. Market Share Analysis
9.1.4. Major Growth Strategy in the global insulin biosimilars market
9.1.5. Competitive Benchmarking
9.1.6. Leading Player in terms of Number of Developments in the global insulin biosimilars market
9.1.7. Key Developments & Growth Strategies
9.1.7.1. Product Launch
9.1.7.2. Merger & Acquisition
9.1.7.3. Joint Ventures
9.1.8. Major Players Financial Matrix
9.1.8.1. Sales & Operating Income 2019
9.1.8.2. Major Players R&D Expenditure 2019
10. COMPANY PROFILES
10.1. Sanofi S.A.
10.1.1. Company Overview
10.1.2. Product Type Overview
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Boehringer Ingelheim
10.2.1. Company Overview
10.2.2. Product Type Overview
10.2.3. Financial Overview
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. Eli Lilly & Co.
10.3.1. Company Overview
10.3.2. Product Type Overview
10.3.3. Financial Overview
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. NOVO Nordisk A/S
10.4.1. Company Overview
10.4.2. Product Type Overview
10.4.3. Financial Overview
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Biocon
10.5.1. Company Overview
10.5.2. Product Type Overview
10.5.3. Financial Overview
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Merck & Co.
10.6.1. Company Overview
10.6.2. Product Type Overview
10.6.3. Financial Overview
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Mylan N.V.
10.7.1. Company Overview
10.7.2. Product Type Overview
10.7.3. Financial Overview
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Pfizer Inc.
10.8.1. Company Overview
10.8.2. Product Type Overview
10.8.3. Financial Overview
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Sandoz
10.9.1. Company Overview
10.9.2. Product Type Overview
10.9.3. Financial Overview
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Fresenius Kabi
10.10.1. Company Overview
10.10.2. Product Type Overview
10.10.3. Financial Overview
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. Others
10.11.1. Company Overview
10.11.2. Product Type Overview
10.11.3. Financial Overview
10.11.4. Key Developments
10.11.5. SWOT Analysis
10.11.6. Key Strategies
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL INSULIN BIOSIMILARS MARKET SYNOPSIS, 2020–2027
TABLE 2 GLOBAL INSULIN BIOSIMILARS MARKET ESTIMATES & FORECAST, 2020–2027 (USD MILLION)
TABLE 3 GLOBAL INSULIN BIOSIMILARS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 4 GLOBAL INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 5 GLOBAL INSULIN BIOSIMILARS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 6 NORTH AMERICA: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 7 NORTH AMERICA: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 8 US: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 9 US: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 10 CANADA: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 11 CANADA: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 12 LATIN AMERICA: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 13 LATIN AMERICA: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 14 EUROPE: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 15 EUROPE: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 16 WESTERN EUROPE: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 17 WESTERN EUROPE: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 18 EASTERN EUROPE: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 19 EASTERN EUROPE: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 21 ASIA-PACIFIC: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL INSULIN BIOSIMILARS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL INSULIN BIOSIMILARS MARKET
FIGURE 4 GLOBAL INSULIN BIOSIMILARS MARKET SHARE, BY TYPE, 2019 (%)
FIGURE 5 GLOBAL INSULIN BIOSIMILARS MARKET SHARE, BY INDICATION, 2019 (%)
FIGURE 6 GLOBAL INSULIN BIOSIMILARS MARKET SHARE, BY REGION, 2019 (%)
FIGURE 7 AMERICAS: INSULIN BIOSIMILARS MARKET SHARE BY REGION, 2019 (%)
FIGURE 7 NORTH AMERICA: INSULIN BIOSIMILARS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 8 EUROPE: INSULIN BIOSIMILARS MARKET SHARE, BY REGION, 2019 (%)
FIGURE 9 WESTERN EUROPE: INSULIN BIOSIMILARS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 10 ASIA-PACIFIC: INSULIN BIOSIMILARS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 11 MIDDLE EAST & AFRICA: INSULIN BIOSIMILARS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 12 GLOBAL INSULIN BIOSIMILARS MARKET: COMPANY SHARE ANALYSIS, 2019 (%)
FIGURE 13 SANOFI S.A.: KEY FINANCIALS
FIGURE 14 SANOFI S.A.: SEGMENTAL REVENUE
FIGURE 15 SANOFI S.A.: REGIONAL REVENUE
FIGURE 16 BOEHRINGER INGELHEIM: KEY FINANCIALS
FIGURE 17 BOEHRINGER INGELHEIM: SEGMENTAL REVENUE
FIGURE 18 BOEHRINGER INGELHEIM: REGIONAL REVENUE
FIGURE 19 ELI LILLY & CO.: KEY FINANCIALS
FIGURE 20 ELI LILLY & CO.: SEGMENTAL REVENUE
FIGURE 21 ELI LILLY & CO.: REGIONAL REVENUE
FIGURE 22 NOVO NORDISK A/S: KEY FINANCIALS
FIGURE 23 NOVO NORDISK A/S: SEGMENTAL REVENUE
FIGURE 24 NOVO NORDISK A/S: REGIONAL REVENUE
FIGURE 25 BIOCON: KEY FINANCIALS
FIGURE 26 BIOCON: SEGMENTAL REVENUE
FIGURE 27 BIOCON: REGIONAL REVENUE
FIGURE 28 MERCK & CO.: KEY FINANCIALS
FIGURE 29 MERCK & CO.: SEGMENTAL REVENUE
FIGURE 30 MERCK & CO.: REGIONAL REVENUE
FIGURE 31 MYLAN N.V.: KEY FINANCIALS
FIGURE 32 MYLAN N.V.: SEGMENTAL REVENUE
FIGURE 33 MYLAN N.V.: REGIONAL REVENUE
FIGURE 34 PFIZER INC.: KEY FINANCIALS
FIGURE 35 PFIZER INC.: SEGMENTAL REVENUE
FIGURE 36 PFIZER INC.: REGIONAL REVENUE
FIGURE 37 SANDOZ: KEY FINANCIALS
FIGURE 38 SANDOZ: SEGMENTAL REVENUE
FIGURE 39 SANDOZ: REGIONAL REVENUE
FIGURE 40 FRESENIUS KABI: KEY FINANCIALS
FIGURE 41 FRESENIUS KABI: SEGMENTAL REVENUE
FIGURE 42 FRESENIUS KABI: REGIONAL REVENUE
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
